Effect of Erector Spinae Plane Block Applied to Painful Herpes Zoster Patients Who Failed to Respond to Pregabalin Treatment on Immunological Marker Levels and Postherpetic Neuralgia Incidence Rate
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 30
- 主要终点
- Change in CD3 levels [CD3 levels will be studied in the blood samples taken. First visit<br>1 day after the block is applied (intervention group) or at the first check-up where it is determined that the patients in the control group have responded to pregabalin treatment and the dose is fixed (control group)<br>At the end of the 3rd month post-baseline];Rate of development of postherpetic neuralgia[Numeric Rating Scale Score At the end of the 3 months];Change in CD4 levels [CD4 levels will be studied in the blood samples taken. First visit<br>1 day after the block is applied (intervention group) or at the first check-up where it is determined that the patients in the control group have responded to pregabalin treatment and the dose is fixed (control group)<br>At the end of the 3rd month post-baseline]
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 80 Years（—）
- 性别
- All
入选标准
- •Volunteers aged between 18 and 80 years, who have passed the acute phase of the disease, whose vesicles have dried, whose antiviral treatment has been completed, who have involvement of thoracic region dermatomes, who have a DN4 score over 4, who have not started neuropathic pain treatment, and who have been diagnosed with herpes zoster whose pain has not become chronic will be included in the study.
排除标准
- •Patients with diabetes mellitus, another disease that may cause neuropathic pain, malignancy, previous treatment for neuropathic pain, bacterial infection in the affected dermatome, autoimmune disease, drug and alcohol addiction, smoking, chronic renal failure and liver failure, immunodeficiency, those who do not agree to participate in the study, and those who are pregnant or breastfeeding will be excluded from the study.
结局指标
主要结局
Change in CD3 levels [CD3 levels will be studied in the blood samples taken. First visit<br>1 day after the block is applied (intervention group) or at the first check-up where it is determined that the patients in the control group have responded to pregabalin treatment and the dose is fixed (control group)<br>At the end of the 3rd month post-baseline];Rate of development of postherpetic neuralgia[Numeric Rating Scale Score At the end of the 3 months];Change in CD4 levels [CD4 levels will be studied in the blood samples taken. First visit<br>1 day after the block is applied (intervention group) or at the first check-up where it is determined that the patients in the control group have responded to pregabalin treatment and the dose is fixed (control group)<br>At the end of the 3rd month post-baseline]
次要结局
未报告次要终点